The Quality of Life of Pseudomyxoma Peritonei Patients: A Scoping Review
Table 1
Study characteristics.
Title
Authors
Country
Year
Paper type
Main aims
Method used to assess QoL
Sample size and characteristics
QOL related results
Quality of life after intraperitoneal chemotherapy for peritoneal carcinomatosis [23]
McQuellon et al.
Saudi Arabia
2004
Research Article
Investigate the impact of infusing intraperitoneal chemotherapy (IPCT) using Cisplatin 50–100 mg/postpalliative abdominal paracentesis to delay fluid accumulation to the abdominal cavity on patients’ symptoms and quality of life
Functional Assessment of cancer treatment General (FACT-G)
N = 12 (of which only 1 had PMP). No demographic data were provided
Both quality of life and symptoms improved after intraperitoneal chemotherapy (IPCT) in the PMP patient
Pseudomyxoma peritonei: Role of cytoreduction and intraperitoneal chemotherapy [17]
Choi et al.
Hong Kong
2004
Case study
Present a case study
NA
N = 1; 61-year-old woman
None
A study to explore the patient’s experience of peritoneal surface malignancies: pseudomyxoma peritonei [5]
Withama et al.
UK
2008
Research Article (qualitative)
Explore the effect of PMP on patients’ lives
A qualitative study design using semistructured individual interviews
N = 13. Six (46%) patients were male and seven (54%) were female. Four (31%) were aged below 50, five (38%) were aged between 50 and 59, and four (31%) were aged over 60
Themes: uncertainty, difficulties confirming diagnosis, and living with an uncertain prognosis
Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study [9]
Jess et al.
Denmark
2008
Research Article
Investigate the impact of cytoreductive surgery plus early intraperitoneal postoperative chemotherapy on quality of life
Short Form-36 questionnaire, EORTC QLQ-C30, EORTC QLQ-CR38
N = 23. The median age was 53.8 men and 15 women
CRIS and EPIC had little impact on quality of life and only shortly after surgery. Scores returned to baseline after 6 months postsurgery
Clinical presentation of pseudomyxoma peritonei [18]
Järvinen and Lepistö
Finland
2010
Research Article
To characterize the manifestations of PMP
Analyzed the hospital records of patients with PMP
N = 82 of which 53 were women and 29 were men. Mean age at the time of diagnosis was 52.3
Abdominal pain was the most common complaint (23%)
Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei [8]
Alves et al.
UK
2010
Research Article
Asses the quality of life of PMP patients at baseline (preoperatively) and postoperatively and compare the quality of life of patients who had a complete surgery (removal of all macroscopic disease) and a major debulk surgery
European Organization for research and treatment of cancer (EORTC) QLQ-C30 questionnaire
N = 49.13 males and 36 females. Median age of 55
QoL improved 1 year after surgery in both the complete cytoreduction and major tumour debulking
Palliative effects of an incomplete cytoreduction combined with perioperative intraperitoneal chemotherapy [22]
Chua et al.
Australia
2010
Research Article
Investigate whether the outcome of an incomplete cytoreduction followed by administering perioperative intraperitoneal chemotherapy prolongs survival or palliates symptoms
A retrospective review of a prospectively collected database of patients’ clinical notes was performed
N = 11.7 males and 4 females. Median age was 54 (only 7 patients had PMP)
Symptomatic benefits occurred in people with incomplete surgery (some disease left). Symptoms improved in 5 PMP patients
Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals [21]
Kitai et al.
Japan
2011
Research Article
This study aims to investigate the benefits and risks of the Sugarbaker procedure
Review the clinical patients with PMP.
N = 15. Four (26.7%) patients were male and eleven (73.3%) were females, with an average age of 60.5 years
After a median follow-up period of 43 months, all of the 12 patients with complete cytoreduction were alive and disease-free with good quality of life
Quality of life study following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei including redo procedures [7]
Kirby et al.
Australia
2013
Research Article
Evaluate the quality of life of pseudomyxoma peritonei following cytoreductive surgery and intraperitoneal chemotherapy
FACT C (version 4) quality of life questionnaire, and FACIT-TS-G (version 1) questionnaires
N = 63, thirty-nine (62%) of the participants were females. Average age of 54 years
There was no significant difference in the quality of life scores between patients who had a single versus redo procedure
Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects [15]
Amini et al.
Australia
2014
Review
Present a review of PMP its diagnosis, treatment and prognosis
NA
0
Not applicable
Can a benefit be expected from surgical debulking of unresectable pseudomyxoma peritonei? [20]
Delhorme et al.
France
2016
Research Article
Evaluate the role of surgical debulking in improving the symptoms of PMP is patients
Retrospective analysis of a database of all patients in a tertiary care center treated for PMP
N = 338.21 (54%) males and 18 (46%) females. The median age was 59
Major tumor debulking can relieve PMP-related symptoms over a median time of almost 2 years
Should total gastrectomy and total colectomy be considered for selected patients with severe tumor burden of pseudomyxoma peritonei in cytoreductive surgery? [19]
Liu et al.
Japan
2016
Research Article
Assess survival morbidity and mortality after CRS as well as perioperatively
EORTC QOL-C30 questionnaire
N = 48. Twenty-eight (58.3%) patients were male and twenty (42%) were female. The median age was 52.5 years
Patients receiving CRS including total gastrectomy and total colectomy could have a similar quality of life as other patients after 6 months postsurgery
Long-term quality of life after cytoreductive surgery and heated intraperitoneal chemotherapy for pseudomyxoma peritonei: A prospective longitudinal study. [10]
Stearns et al.
UK
2018
Research Article
Evaluate long-term health related quality of life (HRQL) for patients with PMP
(EORTC)-QLQ C30 HRQL questionnaire
Study 1: N = 137; (102 females, 74.5%). The median age at surgery was 52.7 years. Study 2: N = 85; median age was 62.5 years
12 months postsurgery, CRS-HIPEC for PMP is associated with a good quality of life except for some cognitive functional impairment and bowel disturbance
